DK2481402T3 - Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer - Google Patents

Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer Download PDF

Info

Publication number
DK2481402T3
DK2481402T3 DK12152455.7T DK12152455T DK2481402T3 DK 2481402 T3 DK2481402 T3 DK 2481402T3 DK 12152455 T DK12152455 T DK 12152455T DK 2481402 T3 DK2481402 T3 DK 2481402T3
Authority
DK
Denmark
Prior art keywords
cancer
rapamycin
composition
derivative
examples
Prior art date
Application number
DK12152455.7T
Other languages
English (en)
Inventor
Vuong Trieu
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Application granted granted Critical
Publication of DK2481402T3 publication Critical patent/DK2481402T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (14)

1. Sammensætning, der omfatter nanopartikler, som omfatter rapamycin eller et derivat deraf og et bærerprotein, til anvendelse i en fremgangsmåde til I behandling af cancer hos et individ, hvor fremgangsmåden endvidere omfatter en anden terapi, hvor den anden terapi omfatter administration af erlotinib, perifosin eller doxorubicin, og hvor derivatet er valgt fra gruppen bestående af benzoyl-rapamycin, oxaazacyclohentriacontin, temsirolimus (CCI 779 (Wyeth)), everolimus (RAD 001 (Novartis)), pimecrolimus (ASM981), 32-deoxo-rapamycin i (SAR943), zotarolimus (ABT-578), ridaforolimus (AP23573) og Biolimus A9.
2. Sammensætning til anvendelse ifølge krav 1, hvor mængden af rapamycin eller derivatet deraf i sammensætningen er i området fra 54 mg til 540 mg.
3. Sammensætning til anvendelse ifølge krav 2, hvor mængden af rapamycin eller derivatet deraf i sammensætningen er i området fra 54 mg til 175 mg.
4. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor den anden terapi omfatter administration af erlotinib. i
5. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor canceren er valgt fra gruppen bestående af blærecancer, multipelt myelom, hjernecancer, pankreascancer, plasmacytom, nyrecellekarcinom, prostatacancer, lungecancer, melanom, brystcancer, mesoteliom, neuroendokrin cancer, i ovariecancer, lymfom, lymfoid neoplasme, myelom, leukæmi, skjoldbruskkirtelcancer, sarkom, HER2-positiv brystcancer, HER2-negativ brystcancer, kronisk myelogen leukæmi, endometriecancer og pladecellekarcinom i hoved og hals.
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor sammensætningen skal administreres ad en intravenøs, intraarteriel, intraperitoneal, intravesikulær, subkutan, intratekal, intrapulmonær, intramuskulær, intratrakeal, intraokulær, transdermal eller oral vej eller via inhalation.
7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, i hvor bærerproteinet er albumin.
8. Sammensætning til anvendelse ifølge krav 7, hvor albuminet er humant serumalbumin.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor den gennemsnitlige diameter for nanopartiklerne, der omfatter rapamycin eller derivatet deraf, ikke er større end ca. 200 nm, fortrinsvis ikke større end ca. 100 nm.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor nanopartiklerne, der omfatter rapamycin eller derivatet deraf, er overtrukket med bærerproteinet.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, i hvor sammensætningen omfatter nanopartikler, der omfatter rapamycin.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor canceren er brystcancer.
13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor fremgangsmåden omfatter administration af sammensætningen ad en intravenøs vej.
14. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 13, i hvor individet er et menneske.
DK12152455.7T 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer DK2481402T3 (da)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US90573507P 2007-03-07 2007-03-07
US90573407P 2007-03-07 2007-03-07
US90566907P 2007-03-07 2007-03-07
US90576707P 2007-03-07 2007-03-07
US90567207P 2007-03-07 2007-03-07
US90578707P 2007-03-07 2007-03-07
US90566307P 2007-03-07 2007-03-07
US90566207P 2007-03-07 2007-03-07
US90575007P 2007-03-07 2007-03-07
US92345607P 2007-04-13 2007-04-13
US92324807P 2007-04-13 2007-04-13
EP08726605.2A EP2131821B1 (en) 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent

Publications (1)

Publication Number Publication Date
DK2481402T3 true DK2481402T3 (da) 2018-08-06

Family

ID=39562000

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12152463.1T DK2481409T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
DK12152455.7T DK2481402T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
DK08726605.2T DK2131821T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12152463.1T DK2481409T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08726605.2T DK2131821T3 (da) 2007-03-07 2008-03-07 Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer

Country Status (24)

Country Link
US (6) US8911786B2 (da)
EP (4) EP2481409B1 (da)
JP (6) JP2010520289A (da)
KR (5) KR101943230B1 (da)
CN (1) CN104814930B (da)
AU (1) AU2008223334B2 (da)
BR (1) BRPI0808635B1 (da)
CA (3) CA3201293A1 (da)
CY (3) CY1120547T1 (da)
DK (3) DK2481409T3 (da)
ES (3) ES2690174T3 (da)
HR (3) HRP20181159T1 (da)
HU (3) HUE038701T2 (da)
IL (2) IL200755A (da)
LT (3) LT2481402T (da)
MX (1) MX2009009537A (da)
NZ (2) NZ621972A (da)
PL (3) PL2131821T3 (da)
PT (3) PT2481409T (da)
RU (3) RU2483714C2 (da)
SI (3) SI2481402T1 (da)
UA (1) UA118645C2 (da)
WO (1) WO2008109163A1 (da)
ZA (1) ZA200906342B (da)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
WO2008076373A1 (en) 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
DK2481409T3 (da) 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
ES2621141T3 (es) * 2008-11-28 2017-07-03 Novartis Ag Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
EA023244B1 (ru) * 2009-04-10 2016-05-31 Хаян Ки Способ предотвращения старения клеток
HUE047376T2 (hu) 2009-04-15 2020-04-28 Abraxis Bioscience Llc Prionmentes nanorészecske-készítmények és elõállításuk
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
JP6242213B2 (ja) 2010-03-29 2017-12-06 アブラクシス バイオサイエンス， エルエルシー 薬物送達および治療用薬剤の有効性を向上させる方法
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
KR20180049180A (ko) 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2012054564A2 (en) * 2010-10-19 2012-04-26 The Curators Of The University Of Missouri Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
SG194623A1 (en) * 2011-04-28 2013-12-30 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
CN103517707A (zh) 2011-04-29 2014-01-15 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
HUE045661T2 (hu) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához
US9731012B2 (en) * 2012-03-30 2017-08-15 President And Fellows Of Harvard College Laser-actuated therapeutic nanoparticles
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
WO2014031649A1 (en) * 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
BR112015005940A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc processo para a preparação de nanopartículas terapêuticas
MX363147B (es) * 2012-09-17 2019-03-11 Pfizer Inc Star Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas.
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
EP2941301A4 (en) * 2013-01-03 2016-08-17 Univ Texas RAPAMYCIN ANALOGUE TREATED ON PROTEASOME FUNCTION IN THE TREATMENT OF CANCER
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
US20160015691A1 (en) * 2013-03-15 2016-01-21 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
KR101329646B1 (ko) 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
KR20220025909A (ko) * 2013-05-03 2022-03-03 셀렉타 바이오사이언시즈, 인크. 면역 관용의 유도를 위한 특정된 약역학적 유효 수명을 갖는 면역억제제 및 항원의 전달
WO2014179771A1 (en) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
MX370490B (es) 2013-09-16 2019-12-16 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
WO2015061468A1 (en) * 2013-10-22 2015-04-30 The University Of North Carolina At Chapel Hill Polymer nanoparticles containing multiple agents and methods thereof
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MX2016012009A (es) 2014-03-14 2016-12-05 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
BR112017001470A2 (pt) 2014-09-07 2018-02-20 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de terapia genética
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
WO2016172069A1 (en) * 2015-04-20 2016-10-27 Washington State University Methods of treating inflammation associated airway diseases and viral infections
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US20180153863A1 (en) * 2015-06-29 2018-06-07 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
CA2990703A1 (en) * 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
WO2017004249A1 (en) * 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
JP2018526334A (ja) * 2015-06-29 2018-09-13 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して血液学的悪性疾患を処置する方法
JP6921802B2 (ja) * 2015-08-18 2021-08-18 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ キャリア結合剤組成物およびそれを作製および使用する方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research INTERFERON CANCER TREATMENT METHODS
CA3013650A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
MX2018009408A (es) 2016-02-04 2018-11-09 Univ Johns Hopkins Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos.
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CN108700566A (zh) 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 免疫原性调节的方法
EP3426301A4 (en) * 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EA201990820A1 (ru) * 2016-09-28 2019-10-31 Способы лечения митохондриальных и метаболических нарушений
IL302385B1 (en) 2017-01-06 2024-02-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
CN110167555A (zh) * 2017-01-06 2019-08-23 参天制药株式会社 用于治疗前列腺癌的西罗莫司瘤内施予
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
WO2019073371A1 (en) 2017-10-11 2019-04-18 Wockhardt Limited PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-LIPID HYBRID NANOPARTICLES
JP2021506839A (ja) * 2017-12-19 2021-02-22 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して結腸がんを処置する方法
WO2019126744A1 (en) * 2017-12-21 2019-06-27 The Angiogenesis Foundation Compositions and methods for treating neoplasia
EP3755303A1 (en) * 2018-02-23 2020-12-30 Biotronik AG Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures
JP2021528362A (ja) * 2018-03-20 2021-10-21 アブラクシス バイオサイエンス， エルエルシー ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
MX2021011230A (es) * 2019-03-19 2022-03-11 Abraxis Bioscience Llc Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
WO2021011753A1 (en) * 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Composite drug particles and uses thereof
EP4051241A4 (en) * 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
CN114945358A (zh) * 2019-11-11 2022-08-26 阿布拉科斯生物科学有限公司 用于纳米颗粒组合物的生物标记
KR102641217B1 (ko) * 2019-12-24 2024-02-29 (주)아이엠지티 항암제가 코팅된 알부민 나노입자 및 이의 제조방법
KR102517033B1 (ko) 2020-07-15 2023-04-03 성균관대학교산학협력단 엔도텔린 수용체 길항제를 봉입한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022125784A1 (en) * 2020-12-10 2022-06-16 Children's Hospital Medical Center Enhanced nanoparticle delivery systems
EP4326260A1 (en) * 2021-04-20 2024-02-28 The Regents of The University of Michigan Pi3k inhibitors, nanoformulations, and uses thereof
KR20240044603A (ko) 2022-09-28 2024-04-05 충남대학교산학협력단 피로인산티아민 알부민 나노클러스터를 포함하는 항암치료용 조성물 및 이의 제조방법
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
EP1683517A1 (en) * 1996-08-19 2006-07-26 American Bioscience, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2294981C (en) * 1997-06-27 2012-04-03 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2000064437A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
WO2000071079A2 (en) 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
RU2322981C2 (ru) * 2001-02-19 2008-04-27 Новартис Аг Комбинация и способ предупреждения рака молочной железы
CA2442849A1 (en) 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
CA2447732A1 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4212921B2 (ja) * 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
KR20180098702A (ko) * 2002-12-09 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
AU2003293529A1 (en) * 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20050038498A1 (en) * 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP3327031A1 (en) * 2004-05-14 2018-05-30 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel
CA2561717A1 (en) 2004-05-17 2005-11-24 Novartis Ag Combination of organic compounds
EP3173072A1 (en) * 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
WO2006053754A1 (en) 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006089207A2 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
BRPI0607139A2 (pt) * 2005-02-18 2009-08-11 M S Abdou conjunto de fixação de osso
KR20070121758A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 면역 억제 화합물의 주사가능한 조성물
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US7514549B2 (en) * 2005-04-16 2009-04-07 Michigan State University Tumor inhibition by modulating sprouty expression or activity
EP1888062A1 (en) 2005-05-16 2008-02-20 Novartis AG The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20070148251A1 (en) * 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CA2662140A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
WO2008076373A1 (en) * 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
DK2481409T3 (da) * 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanopartikel, der omfatter rapamycin og albumin som middel mod cancer
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
MX2011006167A (es) * 2008-12-11 2011-07-28 Abraxis Bioscience Llc Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion.
WO2010105172A1 (en) * 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
CN102458112A (zh) * 2009-04-10 2012-05-16 阿布拉科斯生物科学有限公司 纳米颗粒制剂及其用途
HUE047376T2 (hu) 2009-04-15 2020-04-28 Abraxis Bioscience Llc Prionmentes nanorészecske-készítmények és elõállításuk
NZ598588A (en) * 2009-08-25 2014-05-30 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
BR112012024349A2 (pt) * 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
JP6242213B2 (ja) * 2010-03-29 2017-12-06 アブラクシス バイオサイエンス， エルエルシー 薬物送達および治療用薬剤の有効性を向上させる方法
KR101894689B1 (ko) * 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
SG186109A1 (en) * 2010-06-02 2013-01-30 Abraxis Bioscience Llc Methods of treating bladder cancer
KR20180049180A (ko) * 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US9149455B2 (en) * 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Also Published As

Publication number Publication date
RU2678448C2 (ru) 2019-01-29
IL200755A (en) 2017-12-31
JP6544812B2 (ja) 2019-07-17
EP2481402A2 (en) 2012-08-01
EP2481409A2 (en) 2012-08-01
DK2131821T3 (da) 2018-08-06
KR20170014007A (ko) 2017-02-07
RU2009136992A (ru) 2011-04-20
US20100183728A1 (en) 2010-07-22
LT2481409T (lt) 2018-10-25
EP3417859A1 (en) 2018-12-26
EP2481409A3 (en) 2012-10-10
AU2008223334A1 (en) 2008-09-12
PL2481402T3 (pl) 2018-11-30
CY1120555T1 (el) 2019-07-10
HUE039497T2 (hu) 2019-01-28
AU2008223334B2 (en) 2014-05-08
HRP20181159T1 (hr) 2018-11-02
JP2016011309A (ja) 2016-01-21
HRP20181198T1 (hr) 2018-10-05
JP2017132810A (ja) 2017-08-03
KR20150002886A (ko) 2015-01-07
CN104814930A (zh) 2015-08-05
ES2686150T3 (es) 2018-10-16
BRPI0808635A2 (pt) 2014-08-05
HUE038701T2 (hu) 2018-11-28
IL250445A0 (en) 2017-03-30
BRPI0808635B1 (pt) 2022-06-07
JP2014015487A (ja) 2014-01-30
KR20190009842A (ko) 2019-01-29
LT2481402T (lt) 2018-10-25
SI2131821T1 (sl) 2018-11-30
EP2481409B1 (en) 2018-05-09
LT2131821T (lt) 2018-09-25
US20210322335A1 (en) 2021-10-21
CY1120548T1 (el) 2019-07-10
CY1120547T1 (el) 2019-07-10
EP2131821A1 (en) 2009-12-16
IL200755A0 (en) 2010-05-17
JP2018150381A (ja) 2018-09-27
PT2481402T (pt) 2018-10-18
EP2481402B1 (en) 2018-05-09
JP2010520289A (ja) 2010-06-10
PL2481409T3 (pl) 2018-11-30
RU2013109422A (ru) 2014-09-10
US20240065984A1 (en) 2024-02-29
NZ621972A (en) 2015-09-25
CA2680207A1 (en) 2008-09-12
ES2690174T3 (es) 2018-11-19
UA118645C2 (uk) 2019-02-25
KR102154459B1 (ko) 2020-09-09
CA2680207C (en) 2018-07-03
ZA200906342B (en) 2010-11-24
KR20190130680A (ko) 2019-11-22
RU2483714C2 (ru) 2013-06-10
JP6348698B2 (ja) 2018-06-27
SI2481402T1 (sl) 2018-09-28
JP2020002177A (ja) 2020-01-09
DK2481409T3 (da) 2018-08-06
PL2131821T3 (pl) 2018-11-30
RU2019101632A (ru) 2020-07-22
KR20090118999A (ko) 2009-11-18
US20190022020A1 (en) 2019-01-24
HUE039643T2 (hu) 2019-01-28
WO2008109163A1 (en) 2008-09-12
US20150050356A1 (en) 2015-02-19
HRP20181217T1 (hr) 2018-10-05
KR102047634B1 (ko) 2019-11-21
PT2131821T (pt) 2018-10-10
CA3006137A1 (en) 2008-09-12
PT2481409T (pt) 2018-10-18
SI2481409T1 (sl) 2018-09-28
US20130280336A1 (en) 2013-10-24
KR101943230B1 (ko) 2019-01-28
CA3201293A1 (en) 2008-09-12
ES2690175T3 (es) 2018-11-19
EP2481402A3 (en) 2012-10-17
NZ711695A (en) 2017-05-26
CA3006137C (en) 2023-08-01
MX2009009537A (es) 2009-09-16
CN104814930B (zh) 2019-12-17
EP2131821B1 (en) 2018-05-09
US8911786B2 (en) 2014-12-16

Similar Documents

Publication Publication Date Title
US20240065984A1 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2013204187B2 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2015271950B2 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent